Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on July 9, 2015. The report discloses the entry into a material definitive agreement. Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as Cerulean Pharma Inc.
Key Financial Metrics and Agreement Terms
The filing details a new lease agreement with AstraZeneca Pharmaceuticals Limited Partnership for approximately 22,992 square feet of laboratory and office space in Waltham, Massachusetts.
- Lease Term: December 28, 2015, to February 28, 2021.
- Base Rent: $689,760 annually for the first two years, with annual increases thereafter.
- Security Deposit: $229,920 required in the form of a letter of credit.
- Additional Costs: Company is responsible for its share of operating expenses, utility costs, and real estate taxes.
- Extension Option: Right to extend for one additional three-year term based on market conditions.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the commitment to new fixed operating costs and capital requirements (letter of credit) associated with the new facility lease commencing in late 2015.
Guidance, Risks, and Contingencies
Risks and Contingencies: The lease contains customary provisions allowing the Landlord to terminate the agreement if the Company fails to remedy a default within specified periods or upon the Company's bankruptcy or insolvency.
Management Commentary: The Company intends to file the full Lease agreement as an exhibit to its Quarterly Report on Form 10-Q for the period ending June 30, 2015.
Investor Verification Checklist
- Verify the total projected cost of the lease over the initial five-year term, including estimated operating expenses and rent escalations.
- Confirm the impact of the $229,920 letter of credit requirement on the Company's available liquidity and credit facilities.
- Review the upcoming Form 10-Q for the full text of the Lease to assess specific termination clauses and default definitions.
- Assess whether the new 22,992 square foot space aligns with the Company's current operational capacity and growth plans.